The collaboration entails the development of allogeneic T-cell therapies for up to five shared cancer targets, and development of personalized allogeneic T-cell therapies.
Adaptimmune will be responsible for developing clinical candidates using its induced pluripotent stem cell (iPSC) derived allogeneic platform to produce T-cells (iT cells). Genentech will be responsible for the input TCRs and subsequent clinical development and commercialization.
Adaptimmune will receive $150 million upfront and additional payments of $150 million over five years, unless the agreement is terminated earlier. Adaptimmune may also be eligible to receive research, development, regulatory and commercial milestones potentially exceeding $3 billion in total, and royalties on sales.
Adaptimmune has the right to opt in to a 50/50 U.S. profit/cost share on "off-the-shelf" products. If Adaptimmune elects to opt in, then Adaptimmune will be eligible to share 50 percent of profits and losses from U.S. sales on such products and is eligible to receive ex-U.S. regulatory and sales-based milestone payments, as well as royalties on ex-U.S. net sales.